SCHEMBL13804182

SCHEMBL13804182

CNc1cc2ccccc2c(C)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.44
NCF1 P14598 1/20 0.44
CYP1A2 P05177 3/20 0.41
GPR3 P46089 1/20 0.41
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
HTR3A P46098 1/20 0.37
ALDH1A1 P00352 7/20 0.37
HSD17B10 Q99714 3/20 0.37
HPGD P15428 3/20 0.37
NUDT1 P36639 3/20 0.37
HIF1A Q16665 1/20 0.37
CYP1B1 Q16678 1/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SLC2A1 P11166 1/20 0.37
GAA P10253 1/20 0.36
BPTF Q12830 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isophthalic Acid SCHEMBL27798930 0.83 CDC25B (0.44) CYP1A2ALDH1A1HSD17B10HPGDKDM4E
SCHEMBL13804174 0.78 NCF1 (0.42) CYP2A6NCF1CYP1A2NOS3NOS2
SCHEMBL21786398 0.78 NCF1 (0.42) CYP2A6NCF1CYP1A2NOS3NOS2
SCHEMBL23735857 0.77 NCF1 (0.41) CYP2A6NCF1CYP1A2NOS3NOS2
SCHEMBL12539809 0.77 ADORA3 (0.49) NUDT1KDM4E
SCHEMBL13804185 0.76 NUDT1 (0.53) NCF1CYP1A2ALDH1A1HSD17B10HPGD
SCHEMBL20327160 0.76 NCF1 (0.40) CYP2A6NCF1CYP1A2NOS3NOS2
SCHEMBL11916176 0.75 SMN1; SMN2 (0.63) NOS2ALDH1A1HSD17B10HPGDKDM4E
SCHEMBL9218101 0.74 CYP2A6 (0.50) CYP2A6CYP1A2GPR3ALDH1A1HSD17B10
SCHEMBL637928 0.74 CYP2A6 (0.50) CYP2A6NCF1CYP1A2GPR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 US disclosed
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-07-09 US disclosed
US-9012473-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-21 US disclosed
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-24 US disclosed
US-8722704-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-13 US disclosed
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-07 US disclosed
US-8507524-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-13 US disclosed
CN-101687875-A Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals ASTRAZENECA AB 2010-03-31 CN disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 CYP2A6 1024/4885NCF1 2050/4885CYP1A2 2015/4885
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 CYP2A6 1069/4885NCF1 2119/4885CYP1A2 2017/4885
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 CYP2A6 1069/4885NCF1 2119/4885CYP1A2 2017/4885
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 CYP2A6 945/4885NCF1 1979/4885CYP1A2 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.